Musely Raises $360 Million in Revenue‑Share Deal with General Catalyst’s CVF
, , ,

Musely Raises $360 Million in Revenue‑Share Deal with General Catalyst’s CVF

Direct‑to‑consumer telemedicine platform Musely has secured more than $360 million in non‑dilutive financing from General Catalyst’s Customer Value Fund (CVF). The funding, structured as a revenue‑share agreement rather than an equity investment or traditional loan, provides Musely with capital that will be repaid through a capped percentage of its future revenue. Founded in 2014 as a […]
AstraZeneca’s Breast Cancer Drug Camizestrant Faces Scrutiny from FDA Advisors
, , ,

AstraZeneca’s Breast Cancer Drug Camizestrant Faces Scrutiny from FDA Advisors

AstraZeneca has hit a regulatory roadblock as an FDA advisory committee voiced concerns regarding the clinical methodology behind its experimental breast cancer medication, camizestrant. During a recent review, the panel voted 6-3 against the current data set, questioning if the SERENA-6 Phase 3 trial sufficiently proves that administering the drug earlier in the treatment sequence […]
The Hidden Tax Liability Lurking in Your Long-Term HSA Strategy
, , ,

The Hidden Tax Liability Lurking in Your Long-Term HSA Strategy

Health Savings Accounts (HSAs) have become a cornerstone of modern retirement planning, largely due to their unique triple-tax advantage. By allowing contributions to be tax-deductible, growth to occur tax-free, and qualified withdrawals to remain untaxed, these accounts are increasingly utilized as long-term investment vehicles. A popular strategy involves paying for immediate medical costs out-of-pocket, allowing […]